About
May Health is a clinical-stage medical device company based in Paris, France, focused on developing innovative treatments for women with Polycystic Ovary Syndrome (PCOS). Founded in 2017, the company was previously known as AblaCare and has integrated with the Paris-based accelerator MD Start. The flagship product, Ovarian Rebalancing™, is a minimally invasive procedure aimed at restoring natural ovulation in individuals with PCOS. This outpatient treatment targets ovarian ablation to reduce androgen production without hormones, offering a safe alternative to current fertility options. May Health is conducting clinical trials, including the REBALANCE Study, to validate the therapy's safety and effectiveness under FDA and European Union regulations, with plans for future availability in the US and Europe. May Health's leadership team consists of experienced professionals in medtech, product development, and regulatory affairs. The company has secured significant funding to advance its clinical development and is committed to addressing broader health challenges associated with PCOS, aligning its mission with several United Nations Sustainable Development Goals.
Technologies
Keywords
Company Information
-
Employees 29
-
Founded 2017
-
Annual Revenue $34500000
-
Total Funding $46203780
Location
9 Rue du 4 Septembre, Paris, Ile-de-France, France, 75002